Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia

Journal of Medical Economics · Published 2026-07-31 · DOI 10.1080/13696998.2026.2706988

Free full text

Authors (9)

Mohamed Aseafan, Faisal Azam, Ahmed S. Alanazi, Shaheed Alhumaid, Nawaf H. Almalki, Mohamed Masoud, Zainab Alsharef, Hany Soliman, Mohamed El-Khedr Hassan

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Aseafan, M., Azam, F., Alanazi, A., et al. (2026). Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia. Journal of Medical Economics. https://doi.org/10.1080/13696998.2026.2706988

Related articles

• Cost-utility of first-line dostarlimab plus carboplatin-paclitaxel compared with placebo for patients with pA/rEC: a partitioned survival analysis · Health Economics Review · 2026 · Cites or is cited by this article
• Response to Kirshner et al.: updated cost consequence analyses using requested inputs · Journal of Medical Economics · 2026 · Same journal
• Clinical burden and healthcare resource utilization after allogeneic hematopoietic stem cell transplant for sickle cell disease or β-thalassemia · Journal of Medical Economics · 2026 · Same journal
• Cost-effectiveness of vagus nerve-mediated neuroimmune modulation for the treatment of moderate-to-severe rheumatoid arthritis · Journal of Medical Economics · 2026 · Same journal
• Interpreting per-death productivity estimates in human capital analyses of lung cancer: the role of working-age-restricted denominators · Journal of Medical Economics · 2026 · Same journal
• An unanchored matching-adjusted indirect comparison of the efficacy of zanubrutinib versus ibrutinib for the treatment of relapsed/refractory mantle-cell lymphoma · Journal of Medical Economics · 2026 · Same journal
• Natalizumab is associated with improved relapse outcomes and lower healthcare utilization versus ocrelizumab in treatment-naïve people with multiple sclerosis · Journal of Medical Economics · 2026 · Same journal
• A system dynamics modelling protocol to evaluate the impact of a health financing mechanism for breast cancer pharmacotherapies in Malaysia · Journal of Medical Economics · 2026 · Same journal
• The financial impact of surgical interventions for benign prostatic hyperplasia within a single NHS trust · Journal of Medical Economics · 2026 · Same journal
• From options to decisions: an innovative model for treatment sequencing in relapsing-remitting multiple sclerosis · Journal of Medical Economics · 2026 · Same journal